Veraxa Biotech (NASDAQ:VRXA) Director Acquires $32,700.00 in Stock

Veraxa Biotech Holding AG (NASDAQ:VRXA) Director Christoph Samuel Ziegler acquired 30,000 shares of the firm’s stock in a transaction on Tuesday, October 20th. The stock was purchased at an average price of $1.09 per share, with a total value of $32,700.00. Following the acquisition, the director owned 37,932 shares of the company’s stock, valued at $41,345.88. This represents a 378.21% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Veraxa Biotech Price Performance

Veraxa Biotech stock traded up $0.05 on Wednesday, hitting $1.06. 197,872 shares of the stock traded hands, compared to its average volume of 463,167. Veraxa Biotech Holding AG has a 1 year low of $0.99 and a 1 year high of $27.36.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a research report on Monday, August 31st.

Veraxa Biotech Company Profile

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.